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Abstract 40 
The C-terminal  regions of glucagon-like peptide-1  (GLP-1) bind to the N terminus  of the GLP-1 41 
receptor (GLP-1R), facilitating interaction of the ligand N terminus with  the receptor transmem- 42 
brane domain. In contrast, the agonist exendin-4 relies less on the transmembrane domain, and 43 
truncated antagonist analogs (e.g. exendin 9 –39) may interact  solely with  the receptor N termi- nus. 44 
Here we used mutagenesis to explore the role of residues highly conserved in the predicted 45 
transmembrane helices of  mammalian  GLP-1Rs and conserved in family  B G protein coupled 46 
receptors in ligand  binding and GLP-1R activation. By iteration using information from  the mu- 47 
tagenesis, along with the available crystal structure of the receptor N terminus and a model of the 48 
active opsin transmembrane domain, we developed a structural receptor model with GLP-1 bound and 49 
used this to better  understand  consequences of mutations. Mutation at Y152 [transmem- brane  50 
helix  (TM) 1], R190 (TM2), Y235 (TM3), H363 (TM6), and E364 (TM6) produced  similar 51 
reductions in affinity for GLP-1 and exendin 9 –39. In contrast, other  mutations either  preferen- 52 
tially [K197 (TM2), Q234 (TM3), and W284 (extracellular loop 2)] or solely [D198 (TM2) and R310 53 
(TM5)] reduced GLP-1 affinity. Reduced agonist affinity was always associated with  reduced po- 54 
tency. However, reductions in potency exceeded reductions in agonist affinity for K197A, W284A, 55 
and R310A, while  H363A was uncoupled  from  cAMP generation, highlighting critical  roles of 56 
these residues in translating binding to activation. Data show important roles in ligand  binding 57 
and receptor activation of conserved residues within the transmembrane domain of the GLP-1R. The 58 
receptor structural  model provides insight into the roles of these residues. 59 
 4 
Introduction 60 
Processing of proglucagon within L cells of the intestine results in the formation of a number of peptides 61 
including glucagon-like peptide-1 (GLP-1), which is secreted following nutrient ingestion as a 62 
consequence of both neuroendocrine activity and direct contact of luminal nutrients with L cells.  Along 63 
with gastric inhibitory peptide released from intestinal K cells, GLP-1 is a major incretin hormone, 64 
substantially enhancing the postprandial insulin response through its ability to enhance glucose-65 
dependent insulin release from pancreatic β-cells. 66 
Intestinal GLP-1 exists as truncated versions of the full-length peptide with fasting plasma levels of 67 
GLP-1 7-36 amide and GLP-1 7-37 being approximately equivalent.  However, in response to a meal, the 68 
GLP-1 response is predominantly a result of an increase in GLP-1 7-36 amide (1).  The GLP-1 peptides 69 
mediate their biological effects via a single receptor type belonging to Family (or Class) B of the G-70 
protein-coupled receptor (GPCR) superfamily.  Typical of receptors within Family B, the GLP-1 receptor 71 
(GLP-1R) couples predominantly to Gαs thereby mediating its cellular effects through the production of 72 
cAMP, although coupling to Gαi, Gαo, and Gαq/11 has been reported (2-4).  Given the ability of GLP-1 to 73 
enhance glucose-dependent insulin release, the GLP-1R is an especially attractive target for the treatment 74 
of type 2 diabetes mellitus, particularly as the risk of drug-induced hypoglycaemia is substantially less 75 
than with many current therapeutic approaches.  Furthermore, GLP-1 exerts a range of additional 76 
pancreatic and extra-pancreatic anti-diabetogenic effects that have the potential to enhance its clinical 77 
efficacy.  These include an ability to increase insulin biosynthesis and pancreatic β-cell mass, whilst 78 
suppressing glucagon secretion and appetite (5,6). 79 
GLP-1 is rapidly degraded in vivo by the serine protease dipeptidyl peptidase-IV (DPP-IV) (7,8) 80 
resulting in a plasma half-life of only 1-2 minutes for the biologically active peptide and this has driven 81 
the search for more stable analogues for therapeutic use.  One such compound is exendin-4 (Figure 1), a 82 
39 amino acid peptide from the venom of the Gila monster Heloderma suspectum (9), which shares 53% 83 
sequence identity with GLP-1, is not a substrate for DPP-IV and has proven efficacy in the regulation of 84 
blood glucose levels in diabetic patients (10).  However, peptides provide far from ideal therapeutics and 85 
this has focussed the search for small molecule, orally active agonists of the GLP-1R.   This, in part, has 86 
driven the need for greater understanding of the structure-function relationships between GLP-1 and the 87 
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GLP-1R and also more generally for a better understanding of ligand-receptor interactions and activation 88 
mechanisms in Family B GPCRs. 89 
Binding of peptide ligands to Family B GPCRs is currently described by a two-domain model 90 
(11,12) in which the C-terminus of the peptide binds to the extracellular N-terminal domain of the 91 
receptor with high affinity.  This acts as an ‘affinity trap’, promoting the interaction of the N-terminus of 92 
the ligand with lower affinity sites within the transmembrane domain and/or extracellular loops (EC) of 93 
the receptor, which leads to receptor activation.  Consistent with this, the N-terminal domain of the GLP-94 
1R is critical in GLP-1 binding (13-15).  However, binding to the isolated N-terminal domain of the 95 
receptor occurs with relatively low affinity and full-length GLP-1R is required for high affinity binding 96 
(16,17).  Thus, high affinity binding of GLP-1 would seem to require interactions not only with the N-97 
terminus of the receptor but also with other sites including those with charged residues at the 98 
extracellular boundary of the second and fourth transmembrane helices and in EC1 (15,18,19).  Here we 99 
have identified the contribution to ligand binding and receptor activation of a number of residues lying 100 
within the transmembrane domain of the GLP-1R as predicted by Swiss-Prot (http://www.uniprot.org/; 101 
entry P43220).  These residues are conserved in mammalian GLP-1Rs and the majority show strong 102 
conservation across Family B GPCRs (see Table 1 and Figure 2) suggesting important structural and/or 103 
functional roles.  The consequences of these mutations have been used to inform the structural model of 104 
the receptor, which in-turn has been used to understand how the mutagenesis affected ligand binding and 105 
receptor function. 106 
 107 
Results 108 
Binding of GLP-1 7-36 amide and exendin 9-39 to the WT hGLP-1R and mutated receptors  109 
The human (h) GLP-1R was transiently transfected into HEK-293 cells.  Subsequent assays in which the 110 
binding of 0.1nM 125I-exendin 9-39 to the receptor was competed with either exendin 9-39 (homologous) 111 
or GLP-1 7-36 amide (heterologous) revealed concentration-dependent inhibition of 125I-exendin 9-39 112 
binding (Figure 3).  Analysis of these data revealed a Kd for exendin 9-39 of -9.15±0.10 (n=5, log10 M) 113 
and a KI for GLP-1 7-36 amide of -8.22±0.03 (n=5, log10 M) (Table 2). 114 
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A series of hGLP-1R constructs were generated in which a single residue within a 115 
transmembranehelix (TM) or at the extracellular boundary of such a helix was replaced with alanine.  In 116 
a transient expression system, all of the mutated receptors bound 125I-exendin 9-39, indicating both 117 
synthesis and expression of the constructs (Table 2, Figure 4a,b).  Although there was some variability in 118 
receptor expression levels between experiments, there were a number of mutations where expression was 119 
significantly reduced (Table 2).  In particular Y152A (TM1), R190A (TM2), Y235A (TM3), R310A 120 
(TM5) and H363A (TM6) expression was less than 25% of the wild type (WT) receptor. 121 
With the exception of T391A (TM7), which had no effect, all other alanine substitutions influenced 122 
the binding of one or both ligands (GLP-1 7-36 amide / exendin 9-39) (Figure 4a,b, Table 2).  For 123 
Y152A (TM1), R190A (TM2), Y235A (TM3), H363A (TM6) and E364A (TM6), the affinity of both 124 
GLP-1 7-36 amide and exendin 9-39 were similarly reduced.  In contrast, alanine substitutions at K197 125 
(TM2), Q234 (TM3) and W284 (EC2) preferentially reduced agonist (GLP-1 7-36 amide) affinity, whilst 126 
D198A (TM2) and R310A (TM5) only reduced agonist affinity.  Note that although Swiss-Prot predicted 127 
W284 to be at the top of TM4, our model suggests that this residue may be at the proximal end of EC2, 128 
immediately adjacent to TM4 (see e.g. Fig. 2) and we have therefore used this as the location throughout 129 
the text.  The greatest reductions in ligand affinity resulted from mutation at either H363 or E364 (both 130 
TM6).  The E387A (TM7) mutant was the only construct in which the affinity of exendin 9-39 but not 131 
GLP-1 7-36 amide was reduced, although this was a very modest reduction (~½ log unit). 132 
 133 
Effects of single alanine substitutions on agonist potency  134 
Challenge of HEK-293 cells transiently expressing the WT hGLP-1R with GLP-1 7-37 resulted in a 135 
concentration-dependent increase in cAMP levels with an EC50 value of -10.16±0.22 (n=7, log10 M) 136 
(Table 3, Figure 4c).  The Emax of the WT receptor was 114±34% (n=7) of the response to challenge with 137 
50μM forskolin.  Neither E387A nor T391A (both TM7) influenced agonist affinity (see above) and this 138 
was consistent with a lack of effect on agonist potency (Table 3).  In contrast, agonist potency was 139 
reduced for all the other constructs (Table 3, Figure 4c), consistent with reductions in agonist affinity 140 
(see above).  Of the twelve mutants, only H363A (TM6) was essentially uncoupled from cAMP 141 
generation (Figure 4c, Table 3) although E364A (TM6) also had a reduced Emax (44±25%, n=3 of the 142 
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forskolin response) (Table 3).  In addition to H363A, which was essentially uncoupled despite agonist 143 
binding, the mutations K197A (TM2), W284A (EC2) and R310A (TM5) resulted in much greater 144 
reductions in agonist potency than affinity (Tables 2 and 3).   A similar profile of potency differences 145 
between the wild-type receptor and the mutated receptors was observed irrespective of whether GLP-1 7-146 
37 or GLP-1 7-36 amide was used as the agonist in the functional assays (data not shown). 147 
Although expression levels did vary amongst the receptor constructs, there was little evidence to 148 
suggest this had a major impact on agonist potencies.  For example, despite the expression of Y152A 149 
being substantially lower than the wild-type receptor, agonist potency was reduced in line with affinity.  150 
Indeed, there were no instances where potency but not affinity was reduced.  In many cases, reductions in 151 
agonist potency and affinity were similar, suggesting that reduced potency resulted from reduced agonist 152 
affinity.  However, in a number of mutants (K197A, W284A and R310A) potency was reduced more 153 
than agonist affinity, whilst H363A was uncoupled from cAMP generation.  These constructs did not 154 
show the lowest levels of expression. 155 
 156 
Three-dimensional model and helical wheel projection of the hGLP-1R.  157 
Development of the receptor model was an iterative process in which a number of models were 158 
generated, selected and re-modelled to account for incompatibilities between the model and both data 159 
within the literature and data arising from the analysis of our receptor mutants.  For example, in an 160 
intermediate model (without helix remodelling) some incompatibility was observed between the model 161 
and the mutation data.  As an illustration of this, Y152 was predicted to be on the outer face of TM1, 162 
orientated towards the membrane, and it was difficult to formulate a clear idea about how mutation could 163 
account for the observed reductions in ligand affinity and potency. However, this intermediate model 164 
used the structure of active opsin as a template for the transmembrane domain and did not account for 165 
misaligned secondary-structure features within the helices, such as proline residues.  On re-modelling of 166 
the helices to account for such features (Table 4), the orientation of this residue changed, placing it in an 167 
aromatic pocket between TM1 and TM2 (π-stacking with F195 (TM2) and hydrophobic interaction with 168 
Y148 (TM1)).  This is entirely compatible with the mutation data where Y152A showed a significant 169 
reduction in affinity for both agonist and antagonist binding (predicted from the model as result of this 170 
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pocket collapsing around the much smaller alanine residue).  An additional conservative Y152F mutation 171 
showed no significant change in agonist or antagonist affinities nor a change in potency (Y152F KI, -172 
7.98±0.07; Kd, -9.02±0.10; EC50, -9.93±0.06 versus WT hGLP-1R KI, -8.22±0.03; Kd, -9.15±0.10; EC50, 173 
-10.16±0.22, all data are log10 M, mean±SEM, n=3 for Y152F and n=5 for WT hGLP-1R).  This is 174 
compatible with the space-filling and π-stacking interactions observed with both tyrosine and 175 
phenylalanine residues.  Note that in the vasoactive intestinal peptide receptor 1 (VPAC1) and vasoactive 176 
intestinal peptide receptor 2 (VPAC2) the equivalent residues (Y150 and Y134) have been argued to be 177 
important in stabilizing the active receptor conformation (20). 178 
Two recent studies using photolabile probes of GLP-1 have identified spatial approximations 179 
between F12 of the ligand (L:F12) and Y145 of the receptor (21), between L:A24 and E133 and between 180 
L:G35 and E125 (22), providing potential constraints for any model of the ligand-bound GLP-1R.  In our 181 
early models, L:A24 and E133 were separated by approximately 47Å.  However, E133 (N-terminal 182 
domain) is within a highly flexible loop and this was remodelled, reducing the intermolecular distance to 183 
around 30Å.  Remodelling to reduce this distance further was not compatible with other constraints on 184 
the model.  In our model, L:G35 and E125 (N-terminal domain) are 23Å apart.  The modelling of this 185 
region is based on, and therefore consistent with, the crystal structure of the N-terminal domain of the 186 
GLP-1R with GLP-1 bound (23) and we, therefore, did not remodel this region.  Our model indicates a 187 
distance of approximately 15Å between L:F12 and Y145 (top of TM1), which is acceptable and this 188 
region was not therefore remodelled to accommodate potential interaction over a shorter distance.  It is 189 
important to note that photoaffinity labelling has been used to identify spatial approximations and not to 190 
define interacting residues (21).  Indeed, mutation of E125, E133 or Y145 to alanine had no impact on 191 
either GLP-1 binding affinity or function (21,22), suggesting if any interactions did occur, they are not 192 
critical for receptor structure or function.  Further, it is not clear if such spatial approximations result 193 
from intra- or inter-molecular proximity. 194 
The three dimensional structure of the receptor was examined to investigate the possible interactions 195 
of specific residues and the possible consequences of their mutation (Figure 5).  The approximate 196 
location and orientation of each residue is indicated in the helical wheel model (Figure 6). 197 
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Interactions of the mutated residues with other amino acids in the GLP-1R structure as defined by the 198 
final model are summarised in Table 5.  Each of the residues investigated interacts directly with at least 199 
one other residue and several have the potential to interact with others through water-mediated 200 
interactions.  Interestingly, although mutation of either D198 (TM2) or R310 (TM5) to alanine reduced 201 
receptor affinity for GLP-1 7-36 amide but not exendin 9-39, only D198 directly interacts with the ligand 202 
in our model.  However, R310 interacts with W297 (via a π-stacking interaction) and E364 (via an 203 
electrostatic interaction).  This provides a point of direct contact between TM5 and TM6 near the top of 204 
the helices, which likely stabilises the local loop structure of EC2.  W297 itself is only around 4Å from 205 
the ligand (F12).  Our model also highlights interactions with TM7 by a number of the residues mutated 206 
in the current study.  There is particularly close contact between R190 (TM2) and G395 (TM7) and 207 
between E387 (EC3) and R376 (TM7).  The mutation of T391 (TM7) to alanine had no effect on either 208 
the binding or function of the GLP-1R.  This is consistent with the model, in which T391 is predicted not 209 
to make any significant interactions (only a weak interaction with the aromatic ring of W297 is 210 
predicted).  The relative lack of importance of T391 in Family B GPCR structure is perhaps reflected in 211 
the relative lack of conservation compared to the majority of residues mutated in the present study.  212 
Given that the H363A (TM6) mutation abolished cAMP response to GLP-1 7-37 and that the model 213 
indicates that it makes direct contact with two residues in TM7 (F390 and F393), this suggests that this 214 
link between TM6 and TM7 is critical for GLP-1R function.  In addition to interactions between the 215 
transmembrane helices, interactions between transmembrane helices and EC regions have been 216 
highlighted in Table 5 (e.g. Q234 of TM3 interacts directly with W297 of EC2 and F230 of TM3 217 
interacts with W284 of EC2 via π-stacking).  Interactions between the receptor and the ligand indicated 218 
by the model are highlighted in Table 6. 219 
220 
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Discussion 221 
 222 
Heterologous and homologous competition binding assays demonstrated low nanomolar affinities of 223 
GLP-1 7-36 amide and exendin 9-39 at the hGLP-1R, consistent with previous reports (24-27).  GLP-1 224 
binding likely occurs through an initial, relatively low affinity interaction between the ligand C-terminus 225 
and receptor N-terminus, followed by an interaction of the N-terminus of GLP-1 with the receptor core to 226 
establish high affinity (13,15,16).  This implies that the receptor N-terminal domain constrains the ligand 227 
to facilitate interaction with the transmembrane domain and that a rigid connection exists between these 228 
domains in at least one conformation.  In contrast, the receptor N-terminal domain is predominantly 229 
involved in high-affinity binding of the agonist, exendin-4 (16,28).  Such different requirements for high-230 
affinity binding may result from a stable α-helical structure within exendin-4, with GLP-1 paying an 231 
entropic penalty to form the bioactive conformation before binding (29).  Although removal of the first 232 
two N-terminal amino acids of exendin-4 abolishes agonism, truncation by up to eight amino acids has 233 
no effect on affinity (16) and peptides including exendin 9-39, are high affinity antagonists. 234 
Recently a model of the rat GLP-1R (90.9% identity, 95.9% similarity to the human receptor) bound 235 
to GLP-1 has been presented (30).  This model was based on the N-terminal domain of the corticotropin-236 
releasing hormone receptor 2 (i.e. CRF2) (34.5% identity, 53.4% similarity to rat GLP-1R) and the 237 
transmembrane domain of inactive rhodopsin.  However, this model could not adequately explain the 238 
consequences of a number of our mutations.  For example, this literature model (kindly provided by the 239 
authors) shows Y152 (TM1), W284 (TM4 although EC2 in our model) and E364 (TM6) all orientated 240 
out of the transmembrane domain, into the membrane.  However, our alanine mutations of these residues 241 
demonstrate a significant effect on both agonist and antagonist binding, indicating that these residues 242 
serve a role either interacting with the ligand or structurally in supporting the receptor conformation.  243 
Further, the crystal structure of either the exendin 9-39-bound (29) or GLP-1-bound (23) N-terminal 244 
domain of the human GLP-1R, and a model of opsin in its G-protein-interacting conformation (31) are 245 
now available and we have, therefore, developed an alternative model with the most recently available 246 
and most appropriate data.  The model is intended to predict the biologically relevant agonist-bound 247 
conformation.  Unlike the previous model (30) our model excludes the signal peptide sequence as we 248 
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have shown that this does not form part of the mature, signalling receptor (32).  Sequence differences 249 
between the rat and human GLP-1R are not expected to have significant impact on the overall model. 250 
Alanine substitutions at Y152 (TM1), R190 (TM2), Y235 (TM3), H363 (TM6) and E364 (TM6) 251 
reduced agonist and antagonist affinities to similar extents.  As there is little evidence for interaction 252 
between exendin 9-39 the transmembrane domain, this indicates general structural functions of these 253 
residues.  In contrast, alanine substitutions at K197 (TM2), Q234 (TM3) and W284 (EC2) reduced 254 
agonist affinity preferentially, whilst in D198A (TM2) and R310A (TM5), only agonist affinity was 255 
reduced.  These data are consistent with interaction of GLP-1 but not exendin 9-39 with transmembrane 256 
domain residues and the requirement for such residues to either directly interact with agonist or provide 257 
structure within the binding regions.  The polarity of D198 is important for GLP-1 binding (19) and our 258 
model has been constrained to show the reported direct ionic interaction with H7 of GLP-1(30).  D198 259 
and adjacent residues are also critical for ligand binding in other Family B GPCRs (33-36).  Although 260 
D198 does not make direct contact with other residues, the model suggests it is approximately 9Å from 261 
T149 (TM1), which may allow an interaction via a water molecule.  Interestingly, T149M has been 262 
identified in a patient with type 2 diabetes (37) and the mutation has been shown to reduce agonist but 263 
not antagonist affinity (38).  A link between T149 and D198 could explain the consequence of this 264 
mutation. 265 
Our model suggests that residues immediately adjacent to D198 do not contact the ligand, although 266 
they may be critical in maintaining aspects of receptor structure.  For example, our model suggests an 267 
interaction of K197 (TM2) with S225 (TM3), which are part of a hydrogen-bonding network that 268 
includes Q221 (EC1).  This region is adjacent to the ligand binding domain and the observed 269 
conformation of EC1 is critical to GLP-1 binding.  Substitution of this critical lysine (K197 (TM2)) will 270 
weaken the hydrogen-bonding network and result in a change in the conformation of EC1, with likely 271 
consequences for ligand binding.  This marks an improvement over previous models (in-house 272 
unpublished and 30) in that K197 now has a clear structural role, fitting with the observed reduction in 273 
ligand binding affinity shown here and previously (15).  Such structural requirements may be critical in 274 
other Family B receptors.  For example, in VPAC1 and VPAC2 receptors, the equivalent residues (K195 275 
and K179 respectively) also influence binding of the N-terminus of the agonist (35,36).  A previous 276 
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study has highlighted the importance of residues within EC1 to GLP-1 binding by the GLP-1R.  Thus, 277 
the combined alanine substitution of residues M204 and Y205, but not the single mutants, markedly 278 
reduce GLP-1 affinity most likely through a reduction in the combined size and hydrophobicity of the 279 
side chains (39), consistent with a change in the local conformation.  The model suggests these residues 280 
are at the boundary of TM2 and EC1 and are not orientated towards the ligand.  The model is consistent 281 
with the double-mutant causing changes to the local conformation: especially to EC1 and thus the 282 
interactions of the N-terminal domain and the EC loops.   283 
GLP-1 makes a number of interactions with the receptor (Table 6).  The model shows the ligand to 284 
sit in a shallow groove on the top of the transmembrane domain, from where it makes various 285 
interactions with the receptor.  Thus, the ligand conformation allows D293 of EC2 to interact with H7, 286 
T11, F12 and D15 of the ligand through hydrogen-bonding interactions.  A previous study demonstrated 287 
that mutation of these residues to alanine reduces GLP-1 affinity by 10-100 fold although H7, G10, F12, 288 
T13 and D15 of GLP-1 were suggested as key for direct interactions with the receptor based on binding 289 
and functional studies (40).  Clearly, interpretation of such structure-function studies is difficult in the 290 
context of predicting the sites of interaction and other analyses are required to refine our understanding.  291 
Interactions of the ligand with EC2 may be important to binding and the structure of this region therefore 292 
critical.  Interestingly, although the polar residue R310 (TM5) shows little conservation amongst Family 293 
B GPCRs, our model suggests a salt-bridge with E364 (TM6), providing the only interaction between 294 
TM5 and TM6 in the upper half of the transmembrane domain.  It is possible that mutation of R310 295 
results in a general loss of rigidity and structure that particularly affects EC2 and this may cause of the 296 
observed loss of agonist affinity.  In Family A GPCRs the proposed activation mechanism involves a 297 
crucial rotation of TM6, bringing the top-half of the helix toward TM3 (41,42).  As R310A (TM5) had a 298 
more profound impact on agonist potency than affinity, this suggests that the relative positioning and/or 299 
movement of TM6 and/or TM5 may also be important in the activation of Family B receptors.  300 
Comparison of the active and inactive conformations of opsin (PDB codes 3DQB and 1U19, 301 
respectively) show that the major movement on activation is a shift in the position and tilt of TM6, along 302 
with an increase in the kink angle (31).  Our model, being based on the active opsin structure replicates 303 
this shift, although the position of the helix kink is different owing to the change in the proline position, 304 
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and it is interesting to note that there are significant differences around the TM5/6 region between our 305 
model and the previous literature model (30), both in terms of conformation and alignment.  In the 306 
previous model, EC2 contains a helix not present in this model and R310 was critical in maintaining 307 
secondary structure between this helix and TM5.  Our new model is more in line with the proposed 308 
model for Family A GPCR activation, which is consistent with recent evidence from the Family B PTH1 309 
(43). 310 
Our model suggests that within TM3, Q234 interacts via hydrogen-bonding with W297 in EC2.  This 311 
tryptophan was recently identified as being a point of approximation for L20 of GLP-1 using 312 
photoaffinity labelling and its importance in GLP-1 binding was confirmed by mutational work which 313 
showed that a tryptophan to alanine substitution at this position resulted in no saturable GLP-1 binding 314 
(44).  These residues are approximately 20Å apart in our model.  EC2 is long and inherently flexible and 315 
so fixed points such as this interaction and the cysteine bridge (C226 and C296) observed in Family B 316 
GPCRs (45) are crucial in providing some rigidity to this loop and allowing it to adopt a conformation 317 
suitable for ligand binding, including the placement of D293 and E294.  The Q234A mutation removes 318 
this structural constraint, and allows the loop to be more flexible, which does not favour GLP-1 binding.  319 
Although the affinities of both ligands are affected by the mutation, the predominant effect is on GLP-1 320 
binding.  This hypothesis supports the ligand binding mode of the current structural model and is 321 
inconsistent with the alternative ligand conformation (a single helix). Other connections that may support 322 
EC2 include an aromatic-stacking interaction between W284 of EC2 and F230 on TM3, and hydrogen 323 
bonds between K288 of EC2 and P283 of TM4 and between Y289 of EC2 and Y305 of TM5.  Mutation 324 
of W284 to alanine is also likely to change EC2 conformation and the preferential affect on GLP-1 325 
affinity again implicates this extra-cellular loop in GLP-1 binding, consistent with other recent work 326 
implicating this loop in both binding and receptor activation (46).  Further, mutation of K288 to alanine 327 
reduces GLP-1 affinity (18) and our model indicates that this may result from the importance of this 328 
residue in the conformation of EC2 rather than the result of a direct interaction with the ligand. 329 
As previously suggested (30), we show L:F12 sits in a hydrophobic pocket, and that L:Y19 forms an 330 
electrostatic interaction with the receptor, although our model suggests involvement of N300 rather than 331 
R227 and K288 as was highlighted previously (30).  Additional interactions between E294 and L:T11, 332 
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between G295 and L:H7 and between K202 (TM2) and L:E9 are also highlighted in our model (Table 6).  333 
This latter interaction may explain the reported reduction in GLP-1 affinity in a K202A receptor mutant 334 
(15). 335 
H363 (TM6) is highly conserved in Family B GPCRs and its importance is further emphasized as 336 
mutation to alanine not only reduced both GLP-1 and exendin 9-39 affinity but also abolished functional 337 
responses.  Initial modelling indicated that this residue lay close to other residues but had limited contact.  338 
Given the profound effects of the H363A mutation, the orientation of this residue was selected from a 339 
residue conformation library and refined using Prime (Schrödinger Inc., Portland, OR, U.S.A.) with side-340 
chains in the vicinity of 7.5Å unfrozen during forcefield minimisation.  This refinement indicates that 341 
H363 sits in an aromatic pocket and interacts with F390 and F393 on the adjacent helix (TM7).  It is 342 
reasonable to argue that it serves a structural role, the π-stacking providing a sort of anchor.  Indeed, this 343 
residue is highly conserved in Family B GPCRs and mutation of the equivalent residue in the VPAC1 344 
receptor (N229) markedly reduces cAMP and abolishes Ca2+ responses (47).  Interestingly, mutation of 345 
H363 to glutamine (H363Q) in the GLP-1R had no effect on either ligand affinity or agonist potency 346 
(data not shown).  However, this glutamine substitution may allow for π-stacking and provide similar 347 
functionality to histidine. 348 
Mutation of the residue adjacent to H363 (E364A (TM6)) reduced GLP-1 and exendin 9-39 affinities 349 
and agonist potency to similar extents, suggesting a more general role of this residue in receptor 350 
structure.  E364 within TM6 is in a region critical for peptide binding in other Family B GPCRs 351 
including the secretin (48) and parathyroid hormone (49,50) receptors.  Our model suggests a direct 352 
interaction of this residue with R310 (TM5) and through this hydrogen-bonding network onto Q234 353 
(TM3), providing key structural constraints between transmembrane helices. This is in contrast to the 354 
previous literature model (30) where E364 (TM6) is orientated towards the membrane and mutation 355 
would be predicted therefore to have little effect on ligand affinity. 356 
R190A results in similar reductions in ligand affinities (agonist and antagonist) and agonist potency. 357 
In the Family B, VPAC1, VPAC2 and secretin receptors, the equivalent residues to R190 of the GLP-1R 358 
(R188, R172 and R166 respectively) have been argued to interact with, or come into close proximity 359 
with an aspartic acid residue at position 3 of the endogenous agonists (33,35,36).  In our model R190 is 360 
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in close proximity (around 5Å) with the ligand (H7) and whilst not predicted to interact directly, a water-361 
mediated interaction is possible.  Agonists of the GLP-1R have a comparable glutamic acid residue at the 362 
same position (L:E9) and a different residue (K202) does interact directly with L:E9 (Table 6) and may 363 
serve the same structural role in GLP-1R. 364 
Amongst the mutations, only E387A at the extracellular face of TM7 reduced antagonist but not 365 
agonist affinity, albeit to a small extent.  The model indicates a salt-bridge interaction between E387 and 366 
R376.  As R376 is part of EC3, mutation of E387 would be expected to have an effect on EC3 367 
conformation, which forms part of the groove where the ligand resides.  However, the small effect on 368 
antagonist affinity and data indicating that high affinity binding of exendin 9-39 only requires the 369 
receptor N-terminus (13,16,28), suggests that EC3 has little or no contribution to binding.  The 370 
equivalent mutation in the rat secretin receptor (E351A) does, however, markedly affect binding of 371 
secretin and receptor function, possibly due to loss of a charge-charge interaction between the N-372 
terminus of secretin and the receptor (51).  This is entirely consistent with our model where the N-373 
terminal domain is located in space very close to EC3 (closest approach is ~5Å), however the model is 374 
not sufficiently well-tuned to discern individual residue interactions between N-terminal and 375 
transmembrane domain.  The previous literature model (30) did not show a significant role for E387. 376 
In our model, Y235 is located at the outer face of TM3, in a hydrophobic pocket between TM2 and 377 
TM4.  It makes a hydrogen-bonding interaction with G273 in TM4.  The role of Y235 is largely steric 378 
and mutation to alanine would result in a collapse of the local structure, thereby accounting for the 379 
generally negative effects on ligand binding and agonist potency.  Indeed, the ‘packing’ effect of this 380 
bulky residue is likely to be critical as mutation to phenylalanine had no effect on the measured 381 
parameters (data not shown), which is consistent with phenylalanine substitution at the equivalent 382 
residue in the VPAC1 receptor (47).  This is a clear improvement over the previous literature model (30) 383 
where Y235 is shown to be a structural constraint restricting the flexibility of EC2 through a hydrogen 384 
bond to C226.  This model would predict the same effect for both alanine and phenylalanine, whereas the 385 
reality shows quite different effects. 386 
The current data demonstrate the importance for ligand binding and receptor activation of residues 387 
within the GLP-1R transmembrane domain.  Comparison of agonist potency and ligand affinities also 388 
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highlighted roles for residues conserved across mammalian GLP-1Rs or amongst Family B GPCRs.  The 389 
GLP-1R model has also facilitated understanding of the likely mechanisms through which mutations 390 
influence ligand binding and receptor activation. 391 
  392 
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 Methods 393 
Cell culture 394 
HEK-FlpIn cells were routinely maintained in DMEM supplemented with 10% foetal bovine serum 395 
(FBS) in 160cm2 tissue culture flasks at 37°C in a 5% CO2 humidified atmosphere.  396 
 397 
Generation of GLP-1R cDNA and mutated GLP-1Rs 398 
Wild-type human (h) GLP-1R was amplified by PCR from a vector containing the hGLP-1R and the 399 
product inserted into a PCR-Script vector.  It was then sub-cloned into the pcDNA5-FRT expression 400 
plasmid to generate pcDNA5-FRT-GLP-1R.  Point mutations (see Figure 2, Table 1) were generated 401 
using the Quickchange II Site-Directed Mutagenesis Kit using the pcDNA5-FRT-GLP1R as the starting 402 
template.  Mutations at the sites indicated were all initially by alanine substitution although, as indicated 403 
in text, a number of other substitutions were performed at several sites.  Mutagenic primers were 404 
designed using guidelines from the Quickchange II Site-Directed Mutagenesis kit and coding sequences 405 
for the mutated receptors contained a start codon, stop codon and an appropriately positioned Kozak 406 
sequence.  All sequences were confirmed by automated sequence analysis.  Further details of the cloning 407 
strategy are available on request. 408 
 409 
Homologous and heterologous competition binding assays 410 
In order to explore the structure-function relationships for the binding of ligands thought to interact with 411 
either the N-terminal and transmembrane domain or predominantly the N-terminal domain, heterologous 412 
(GLP-1 7-36 amide) and homologous (exendin 9-39) competition binding assays were performed 413 
respectively using 125I-exendin 9-39 as the radioligand as described below. 414 
a) Transfection of cells.  The growth media of cells in 160cm2 flask at approximately 80% 415 
confluency was replaced with OptiMEM media and the cells transfected using a 1:4 ratio of DNA to 416 
Lipofectamine 2000 reagent (e.g. 20μg DNA and 80μl Lipofectamine 2000) following the 417 
manufacturer’s instructions.  Cells were then cultured for 6h before the media was replaced with normal 418 
growth media.  After a further 42h, cells were used as described below. 419 
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b) Membrane preparation. Adherent cells were removed from tissue culture flasks using Accutase 420 
and washed in Dulbecco’s phosphate-buffered saline before being pelleted by centrifugation (600g, 421 
10min, 4°C).  The pellets were then re-suspended in ice-cold membrane buffer (20mM HEPES, 1mM 422 
EDTA, 1mM EGTA, pH 7.4) containing protease inhibitor cocktail (1 tablet 50ml-1) and homogenised 423 
using 50 strokes of a Dounce Glass Homogeniser (Fisher Scientific, Loughborough, U.K.).  The 424 
homogenate was then centrifuged at 600g for 10min at 4°C.  The resulting supernatant was then 425 
centrifuged at 48,000g for 1.5h at 4°C and the resulting pellet re-suspended in ice-cold membrane buffer.  426 
Samples were stored at -80°C until use.  427 
c) Assay. Membrane-based binding assays were carried out in round-bottomed 96-well plates in a 428 
total volume of 200μl with component parts being diluted in assay buffer (Hank’s Balanced Salt Solution 429 
(HBSS); 1.26mM CaCl2, 0.493mM MgCl2, 20mM HEPES, 0.1% (w/v) BSA, pH 7.4).  Initial titration 430 
experiments were performed to determine the concentration of each membrane giving a maximal total 431 
binding of approximately 1500-2000c.p.m. and ligand depletion of <10%.  For the assay itself, 432 
membranes, 125I-exendin 9-39 (final concentration 0.1nM) and either exendin 9-39 (homologous 433 
competition assays) or GLP-1 7-36 amide (heterologous competition assays) at a range of concentrations 434 
were added and binding allowed to proceed to equilibrium at room temperature for 4h.  Using a Brandel 435 
Cell Harvester that had been washed with 2% (w/v) BSA, membranes were collected on Whatman GF/C 436 
glass fibre filters pre-soaked in 0.5% polyethyleneimine.  Membranes were then washed with ice-cold 437 
buffer (composition: 25mM HEPES, 1.5mM CaCl2, 1mM MgSO4, 100mM NaCl, pH 7.4) and filters 438 
allowed to dry.  Bound radioactivity was determined using a TopCount-NXT liquid scintillation counter 439 
(PerkinElmer Life and Analytical Sciences, Waltham, MA, U.S.A.). 440 
d) Data analysis.  For each receptor construct, homologous competition binding curves were 441 
constructed assuming one class of binding site.  The Kd and Bmax values were determined using standard 442 
analysis of homologous competition binding data (GraphPad Software Inc., CA, U.S.A.).  Heterologous 443 
competition binding curves were similarly constructed and the Cheng-Prusoff equation applied to 444 
calculate the KI values for GLP-1 7-36 amide using an affinity estimate determined by standard analysis 445 
of homologous competition binding data (GraphPad Software Inc., CA, U.S.A.) and also the Kd of 446 
exendin 9-39 determined from the homologous competition binding assays.  Heterologous competition 447 
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binding data were compared using a ‘one-site’ and ‘two-site’ fit (GraphPad Software Inc., CA, U.S.A.) 448 
but in all cases were best fit by the one-site model (P>0.05, data not shown), which has therefore been 449 
presented.  Data are expressed as mean±SEM unless otherwise stated.  Statistical analysis was by one-450 
way ANOVA and, where P<0.05, followed by Dunnett’s post-hoc test against the wild-type (WT) hGLP-451 
1R. 452 
 453 
Generation and measurement of cAMP 454 
a) Transfection of cells.  HEK-293 cells were seeded into 6 well tissue culture plates (1x106 cells 455 
well-1) in culture media and allowed to adhere overnight.  The medium was then changed to OptiMEM 456 
and cells transfected with 2μg DNA and 8μl Lipofectamine 2000 per well following the manufacturer’s 457 
instructions.  Cells were cultured for 6h before the media was replaced with cell culture media.  After a 458 
further 42h cells were used as described below. 459 
b) Assay.  Media was removed, the cells collected using Accutase and pelleted by centrifugation 460 
(170g, 5min).  Cells were washed in assay buffer (HBSS; 1.26mM CaCl2, 0.493mM MgCl2, 20mM 461 
HEPES, 0.1% (w/v) BSA, pH 7.4) collected by centrifugation and re-suspended at a density of 0.526x106 462 
cells ml-1 in assay buffer containing 1mM 3-isobutyl-1-methylxanthine (IBMX).  After 15 min, cells 463 
were added to round-bottomed 96 well plates (95,000 cells well-1) containing either GLP-1 7-37 at a 464 
range of concentrations or alternatively 50μM forskolin (FSK) to directly activate adenylyl cyclase.  465 
Plates were incubated at 37°C for 1h before terminating stimulations with 100μl of lysis buffer (cAMP 466 
Biotrak Enzymeimmunoassay System kit).  cAMP levels were then determined following the 467 
manufacturer’s instructions. 468 
c) Data analysis.  A standard curve was constructed and interpolated to determine the concentration 469 
of cAMP.  Data are expressed as a percentage of the cAMP produced in response to 50μM FSK.  470 
Concentration-response curves were fitted (GraphPad Software Inc., CA, U.S.A.) and EC50 values 471 
determined.  These are expressed as mean±SEM.  Statistical analysis was by one-way ANOVA and, 472 
where P<0.05, followed by Dunnett’s post-hoc test against the WT hGLP-1R. 473 
 474 
Three-dimensional model and helical wheel projection of the hGLP-1R 475 
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A three-dimensional model of the human GLP-1R (T29-L422) in complex with GLP-1 was constructed 476 
through a process of comparative modelling.  Initial modelling was performed using MOE (Chemical 477 
Computing Group, Montreal, Quebec, Canada), whilst subsequent refinement and optimisation was 478 
performed using Prime (Schrödinger Inc., Portland, OR, U.S.A.).  To model the receptor in its active 479 
state the structure of active opsin (31) (PDB code: 3DQB) was used as a template for the transmembrane 480 
domain.  Initial alignment of these two sequences followed the principles laid out by Bissantz (52) in 481 
aligning Family A and Family B GPCRs.  The alignment of the second extracellular loop was set so as to 482 
conserve the important crosslink between Cys226 and Cys296, observed in Family B GPCRs (45).  The 483 
structure of the human β2 adrenergic receptor has just been reported, stabilized in an agonist-bound active 484 
state by a camelid antibody fragment (nanobody) that mimics Gαs binding (42).  The structural changes 485 
on activation are very similar to those of the active state of opsin, used for homology modelling in the 486 
present study, and consequently the use of the active state β2AR structure as a template would not be 487 
expected to enhance the model further. 488 
For each modelling run, ten different models were constructed, based on alternative amino acid 489 
conformations, employing the AMBER99 force field.  The best model, according to the scoring function, 490 
was selected for further refinement.  The extracellular loops EC1 and EC2 were rebuilt (part of EC2 was 491 
retained to maintain the Cys crosslink) to create space to accommodate the GLP-1 ligand.  The ligand 492 
was manually docked into the cavity and its position refined using the AMBER99 force field.  The bound 493 
ligand conformation is modelled as two α-helical regions with a flexible region connecting the two (53).  494 
As the precise conformation of the ligand where it interacts with the transmembrane domain is unknown, 495 
this region (H7-F12) was modelled with the various conformations of the solution NMR structure of 496 
exendin-4 (1JRJ) as the template.  The best five conformations were manually selected and the local 497 
structure allowed to relax within the forcefield.  The best-fitting of these was then chosen by manual 498 
inspection. The N-terminal domain structure is taken from the X-ray crystal structure of this isolated unit 499 
(23) (PDB code: 3IOL). Though the relative orientation of the N-terminal domain and transmembrane 500 
domain is uncertain, some interactions between the ligand and the transmembrane domain (19) and 501 
between the ligand and the N-terminal domain (from the crystal structure) are understood.  Therefore in 502 
constructing the model we were guided by the placement of the ligand with respect to both domains.  The 503 
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connecting loop between these two domains was built from residue structure libraries and optimised with 504 
the AMBER99 force field. 505 
One of the difficulties in modelling Family B GPCRs is the differing positions of proline residues 506 
between the model sequence and the template.  Proline, being unable to take part in hydrogen-bonding 507 
necessary for helix formation, results in a pronounced kink in the helix.  Failure to account for this 508 
misalignment would mean a kink in the model where no kink is due and no kink where a proline residue 509 
is located.  In an effort to account for this, the helices where proline misalignment was identified were 510 
modelled based on alternative templates.  A search of the PDB revealed no template structures with high 511 
similarity to the sequences of the individual helices.  Therefore, the alternative templates used were the 512 
other transmembrane helices of the opsin structure, aligned in place to override the original template as 513 
indicated in Table 4.  These override sections were specifically aligned to match the proline position and 514 
the best of the available templates chosen by RMSD to the original template at either end of the helix. 515 
For illustration, a helical wheel projection was constructed from the final model (using a program by 516 
Armstrong and Zidovetzki, available from http://rzlab.ucr.edu/scripts/wheel) to best represent the 517 
orientation of the residues in the upper (extracellular face) sections of the transmembrane domain. Some 518 
simplifications have been made; for example, kinks are not represented and the relative position of each 519 
helix is set by the location close to the ligand binding site. Some helices, particularly TM3, are not 520 
perpendicular to the membrane and so are less well-represented by the helical wheel model, towards the 521 
intracellular side of the membrane. 522 
 523 
Materials 524 
All tissue culture plastics were purchased from Nunc (VWR International, Lutterworth, U.K.).  DMEM, 525 
OptiMEM, FBS, HBSS, Lipofectamine 2000, One Shot TOP10 competent cells, pcDNA5/FRT and 526 
HEK-FlpIn cells were purchased from Invitrogen (Paisley, U.K.).  Accutase was obtained from 527 
Innovative Cell Technologies (San Diego, CA, U.S.A.).  GLP-1 7-36 amide, GLP-1 7-37 and exendin 9-528 
39 were purchased from Bachem (Weil am Rhein, Germany).  The cAMP Biotrak Enzymeimmunoassay 529 
kit was obtained from Amersham Biosciences (GE Healthcare U.K. Ltd, Little Chalfont, U.K.).  530 
Whatman GF/C glass filters and 125I-exendin 9-39 (specific activity 2200Ci mmol-1) were obtained from 531 
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PerkinElmer (Waltham, MA, U.S.A.).  Complete protease inhibitor cocktail tablets were purchases from 532 
Roche Diagnostics (Basel, Switzerland).  All primers for mutagenesis and sequencing were obtained 533 
from Eurogentec (Southampton, U.K.).  Pfu Turbo Hotstart PCR master mix, PCR-Script and the 534 
QuickChange (II and XL) Site-Directed mutagenesis kits were purchased from Stratagene (La Jolla, CA, 535 
U.S.A.).  QIAquick Gel Extraction Kit, QIAquick PCR purification kit, QIAprep Spin Miniprep Kit and 536 
Qiagen HiSpeed Plasmid Maxi-prep kit were all obtained from Qiagen (Crawley, U.K.).  Restriction 537 
enzymes were from New England Biolabs (Ipswich, MA, U.S.A.).  All other chemicals and reagents 538 
were purchased from Sigma-Aldrich (Gillingham, U.K.). 539 
  540 
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Table 1. Comparison of mutation sites in the GLP-1R with the equivalent sites in Family B GPCRs 688 
with known ligands. 689 
 690 
 691 
GPCR GLP-1R residue and equivalent residue in other GPCRs 
GLP-1R 
 
Y152 
TM1 
R190 
TM2 
K197 
TM2 
D198 
TM2 
Q234 
TM3 
Y235 
TM3 
W284 
EC2 
R310 
TM5 
H363 
TM6 
E364 
TM6 
E387 
TM7 
T391 
TM7 
CALCR H N H L * * H H Q F M I 
CALCRL H N H L L * H H E F M M 
CRF1 H * F V N * * Q T Y N E 
CRF2 H * F L N * * Q T Y N Q 
GlucagonR * K I * * * * * * * D S 
GHRHR H K * * H F * K * Y * G 
GIP-R * * R * * * * * * * * S 
GLP-2R * * * * H * * * * * Q S 
PAC1 * * * * H * * K * Y * G 
PTH1 * * * * L * * Q * Y * N 
PTH2 * * * * I * * Q * Y * N 
SecretinR * * * * * * * * * Y * G 
VPAC1 * * * * * * * K * Y * G 
VPAC2 * * * * * * * * * Y * G 
 692 
Sequences of the human Family B GPCRs were aligned using the multiple sequence alignment tool in 693 
ClustalW (http://www.clustal.org).  Residues of the GLP-1R are indicated along with their likely 694 
location.  Where residues are identical between the GLP-1R and the comparator Family B GPCR, this is 695 
designated by an asterisk.  Where residues show conservative differences, these are shown in normal 696 
text.  Where residues are not conserved, these are shown in underlined, bold italics.  Conservation or lack 697 
thereof is based on the BLOSUM62 substitution matrix (54) with residues being considered conserved 698 
with a score of ≥0.  Note that of the residues mutated in the GLP-1R, least conservation is shown in 699 
CALCR, CALCRL, CRF1 and CRF2, whilst some residues, particularly E364 and T391 show the least 700 
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conservation across the receptors.  These residues shown are entirely conserved in the GLP-1R across 701 
mammalian species including human, chimpanzee, sheep, dog, rat, mouse and rhesus monkey with the 702 
exception of a conserved arginine substitution at K197 in dog and a non-conserved asparagine 703 
substitution at Y152 in rhesus monkey.  Key: CALCR, calcitonin receptor; CALCRL, calcitonin 704 
receptor-like receptor; CRF1, corticotrophin-releasing factor receptor 1; CRF2, corticotrophin-releasing 705 
factor receptor 2; glucagonR, glucagon receptor; GHRHR, growth hormone releasing hormone receptor; 706 
GIP-R, gastric inhibitory polypeptide receptor; GLP-2R, glucagon-like peptide-2 receptor; PAC1, 707 
pituitary adenylate cyclase activating polypeptide 1 receptor type I; PTH1, parathyroid hormone receptor 708 
1; PTH2, parathyroid hormone receptor 2; secretinR, secretin receptor; VPAC1, vasoactive intestinal 709 
peptide receptor 1; VPAC2, vasoactive intestinal peptide receptor 2. 710 
  711 
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Table 2. KI of GLP-1 7-36 amide (agonist) and Kd of exendin 9-39 (antagonist) for the WT and 712 
mutated hGLP-1Rs. 713 
 714 
 715 
Using 125I-exendin 9-39 as the radiolabel, homologous and heterologous competition binding assays were 716 
carried out on membranes of HEK-293 cells transiently expressing either the WT hGLP-1R or hGLP-717 
1Rs with single alanine substitutions in their transmembrane domain.  Homologous binding curves were 718 
fitted to determine the Kd for the antagonist exendin 9-39 at each of the receptors and KI values 719 
calculated using the Cheng-Prusoff correction on IC50 values generated from sigmoidal displacement 720 
curves using the agonist GLP-1 7-36 amide as the competing ligand.  The expression levels of the 721 
receptors in each assay were calculated and are expressed as pmol mg-1 protein.  *, P<0.05; **, P<0.01 722 
Receptor Location of 
mutation 
 
KI (Log10 M) 
(GLP-1 7-36 amide) 
Kd (Log10 M) 
(exendin 9-39) 
Receptor levels 
(pmol mg-1 protein) 
WT  -8.22±0.03 -9.15±0.10 27.50±3.44 
Y152A TM1 -6.72±0.37 ** -8.13±0.13 ** 1.84±0.56 ** 
R190A TM2 -6.78±0.12 ** -8.36±0.12 ** 1.98±0.43 ** 
K197A TM2 -6.86±0.04 ** -8.67±0.09 * 15.77±2.77 * 
D198A TM2 -6.59±0.04 ** -8.74±0.20 18.18±5.94 
Q234A TM3 -7.12±0.04 ** -8.63±0.08 * 7.32±1.45 ** 
Y235A TM3 -6.84±0.15 ** -7.88±0.12 ** 3.29±0.84 ** 
W284A EC2 -6.77±0.41 ** -8.49±0.22 ** 9.33±4.74 ** 
R310A TM5 -7.22±0.13 ** -8.81±0.14 4.73±1.36 ** 
H363A TM6 -6.23±0.16 ** -7.53±0.08 ** 6.65±0.53 ** 
E364A TM6 -6.46±0.10 ** -7.28±0.03 ** 11.59±0.36 ** 
E387A TM7 -8.09±0.08 -8.56±0.01 * 28.24±1.82 
T391A TM7 -7.77±0.09 -8.70±0.06 17.75±3.17 
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compared to WT hGLP-1R.  Data are mean±SEM with n=5 for the WT receptor and n=3 for each of the 723 
mutants.  Single underlined are those mutations in which either agonist but not antagonist affinity was 724 
reduced or in which the reduction in agonist affinity was greater than the reduction in antagonist affinity, 725 
whereas a double underline (E387A only) indicates that the reduction in antagonist affinity was greater 726 
than the reduction in agonist affinity.  These were determined by calculating the change in affinity 727 
between the WT hGLP-1R and each mutant for both the agonist and antagonist (i.e. WT KI - mutant KI 728 
and WT Kd - mutant Kd).  For each mutant, the ratio of the differences in KI and Kd values was then 729 
calculated.  A ratio of  >2 was taken to indicate that binding affinity of the agonist, GLP-1 7-36 amide, 730 
was more severely affected than the binding affinity of the antagonist, exendin 9-39, whereas a ratio of 731 
<0.5 was taken to indicate that binding affinity of exendin 9-39 was more severely affected than the 732 
binding affinity of GLP-1 7-36 amide. 733 
734 
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Table 3. Agonist potency for cAMP generation by WT and mutated hGLP-1Rs.   735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
 749 
 750 
 751 
 752 
 753 
HEK-293 cells transiently transfected with either the WT hGLP-1R or hGLP-1Rs with single alanine 754 
substitutions in their transmembrane domain were stimulated, in the presence of 1mM IBMX, for 1h with 755 
varying concentrations of GLP-1 7-37 or FSK (50μM) at 37°C.  The cAMP was extracted and measured 756 
and expressed as a proportion of the response to FSK.  Sigmoidal concentration-response curves were 757 
fitted to allow determination of EC50 and Emax values.  Data are mean±SEM with n=7 for the WT 758 
receptor and n=3 for each of the mutants.  **, P<0.01 compared to the WT receptor.  Underlined are 759 
those mutations in which cAMP responses were either not detectable or in which the reduction in EC50 760 
was greater than the reduction in agonist affinity, KI (see Table 2).  In constructs in which potency was 761 
measurable and significantly reduced, for both the EC50 and KI values, the change between the mutant 762 
Receptor Location of 
mutation 
 
EC50 (Log10 M) Emax  
(% FSK response) 
WT  -10.16±0.22 114±34 
Y152A TM1 -8.92±0.08 ** 96±17 
R190A TM2 -7.93±0.09 ** 112±16 
K197A TM2 -7.36±0.04 ** 85±7 
D198A TM2 -7.17±0.09 ** 77±9 
Q234A TM3 -8.51±0.22 ** 179±96 
Y235A TM3 -8.82±0.12 ** 80±27 
W284A EC2 -7.03±0.03 ** 183±102 
R310A TM5 -7.06±0.13 ** 130±74 
H363A TM6 not detected  
E364A TM6 -8.99±0.03 ** 44±25 
E387A TM7 -9.77±0.06 172±97 
T391A TM7 -10.21±0.15 93±9 
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and the WT hGLP-1R was determined and the ratio of the differences in EC50 and KI values was then 763 
calculated.  A ratio of >2 was taken to indicate that the potency (EC50) of the agonist GLP-1 was more 764 
severely affected than its binding affinity (KI).    765 
766 
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Table 4. Comparison of the sequences of opsin and the GLP-1R. 767 
 768 
 769 
                 __________TM1____________ 770 
FROM TM3                GGEIALWSLVVLAIERY  771 
OPSIN    YLAEPWQFSMLAAYMFLLIVLGFPINFLTLYVTVQHKKLRTPLN 772 
GLP-1R   SPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCT--RN 773 
            *   *                           *       * 774 
         ___________TM2_____________ 775 
OPSIN    YILLNLAVADLFMVLGGFTSTLYTSLHGYFVFG----------- 776 
GLP-1R   YIHLNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQ 777 
         ** ***        *  *                  778 
            _#____________TM3_______________ 779 
OPSIN    -PTGCNLEGFFATLGGEIALWSLVVLAIERYVVVCKPMSNFRFG         780 
GLP-1R   DSLSCRLVFLLMQYCVAANYYWLLVEGVYLYTLLAFSV---FSE 781 
             * *               * *     *        782 
         _________TM4___________            # 783 
FROM TM6   IIMVIAFLICWVPYAS 784 
OPSIN    ENHAIMGVAFTWVMALACAAPPLAGWSRYIPEGMQCSCGIDYYT 785 
GLP-1R   QWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDE--GC-------- 786 
                *   *   *    *       *  *   * 787 
                 ________________TM5_______________ 788 
FROM TM6          AFLICWVPYASVAFY 789 
OPSIN    PHEETNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQ 790 
GLP-1R   -WTRNSNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKA-- 791 
               *                             *    *  792 
            ______________TM6_______________ 793 
FROM TM1              FLLIVLGFPINFLTLYVT 794 
OPSIN    QESATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGS 795 
GLP-1R   -NLMCKTDIKCRLAKSTLTLIPLLGTHEVIFAFVMDEHARGT-- 796 
                                     *  * *       797 
               _________TM7___________ 798 
FROM TM2        LAVADLFMVLGGFTSTLYT  799 
OPSIN    DFGPIFMTIPAFFAKSAAIYNPVIYIMMNKQFRNCMVTTLCCGK 800 
GLP-1R   -LRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERWR 801 
             *       *           *   *               802 
 803 
 804 
Sequence alignment of human GLP-1R (S136-R421) with bovine opsin, determined by the method 805 
described by Bissantz (52).  As the position of proline residues (highlighted) in the transmembrane 806 
helices differ between template and target, alternative templates (in italics) were used to model the shape 807 
of helices where these misalignments occur.  The templates used were from opsin and were used to 808 
create the correct secondary structure at the location of these proline residues and to remove the effect of 809 
a template proline where none existed in the target.  * indicates conserved residues, # indicates the 810 
location of the important C226-C296 bridge (45). 811 
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Table 5. Interactions between mutated residues and the surrounding GPCR structure. 812 
 813 
Residue Location  Orientation Directly interacts with 
Y152 TM1 inner Y148 (TM1, HP) 
F195 (TM2, AR) 
R190 TM2 inner F187 (TM1, AR) 
N240 (TM3, ES) 
K197 TM2 outer S225 (TM3, ES) 
D198 TM2 inner H7 (L, ES) 
Q234 TM3 inner W297 (EC2, ES) 
R310 (TM5, ES) 
Y235 TM3 outer L189 (TM2, HP) 
S193 (TM2, HP) 
P277 (TM4, HP) 
L278 (TM4, HP) 
W284 EC2 inner F230 (TM3, AR) 
Y289 (TM5, AR) 
Y291 (EC2, AR) 
R310 TM5 inner Q234 (TM3, ES) 
W297 (EC2, AR) 
E364 (TM6, ES) 
H363 TM6 inner L359 (TM6, ES) 
F390 (TM7, AR) 
F393 (TM7, AR) 
E364 TM6 inner Y241 (TM3, ES) 
R310 (TM5, ES) 
E387 TM7 inner R376 (EC3, ES) 
T391 TM7 inner W297 (EC2, AR) 
 814 
 815 
Based on the final model generated, the interactions of each of the mutated residues with other amino 816 
acids are presented, including electrostatic interactions (hydrogen-bonds and charge attraction), aromatic 817 
π-interactions and hydrophobic interactions (Van der Waals forces).  Indicated in brackets are the 818 
location of these amino acids within the GLP-1R structure and the type of interaction between the 819 
residues (ES=electrostatic, AR=aromatic; HP=hydrophobic).   820 
 821 
822 
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Table 6.  Sites of interaction between GLP-1 and the GLP-1R. 823 
Receptor residue Location Directly interacts with ligand residue 
D198 TM2 H7 (ES) 
K202 TM2 E9 (ES) 
D293 EC2 H7 (ES) 
T11 (ES) 
F12 (AR) 
D15 (ES)  
E294 EC2 T11 (ES) 
G295 EC2 H7 (ES) 
W297 EC2 F12 (HP) 
N300 EC2 Y19 (ES) 
 824 
Based on the final model generated, the interactions of residues within the receptor transmembrane 825 
domain and residues of the ligand are presented, including electrostatic interactions (hydrogen-bonds and 826 
charge attraction), aromatic π-interactions and hydrophobic interactions (Van der Waals forces).  827 
Indicated in brackets are the location of these amino acids within the GLP-1R structure and the type of 828 
interaction between the residues (ES=electrostatic, AR=aromatic; HP=hydrophobic).  829 
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Figure legends 830 
 831 
Figure 1.  Amino acid sequences of ligands of the GLP-1R.  The aligned amino acid sequences of 832 
the GLP-1R agonists GLP-1 7-36 amide, GLP-1 7-37 and exendin-4 are shown alongside that of the 833 
antagonist exendin 9-39.  The residues highlighted in bold are conserved between GLP-1 and exendin. 834 
 835 
Figure 2.  Schematic representation of the transmembrane domain and connecting loops of the 836 
hGLP-1R.  The linear sequence was obtained from the NCBI database (rs1042044; var105098 as used in 837 
the present study).  Residues mutated in the present study are shown by white text in black circles.  All of 838 
these residues are fully conserved across the cloned mammalian GLP-1Rs (chimpanzee, dog, human, 839 
mouse, rat, rhesus monkey, sheep) with the exceptions of K197, which has a conservative substitution of 840 
arginine in the dog sequence and Y152 which is replaced by serine in the rhesus monkey sequence.  841 
Dashed lines indicate missing residues. This representation is based on our final model of the GLP-1R 842 
and differs slightly from the transmembrane helices identified in the Swiss-Prot entry (P43220).  Note 843 
that although W284 was selected for mutation based on its location in TM4 as suggested in Swiss-Prot, 844 
our model suggests that this residue is at the proximal end of EC2, immediately adjacent to TM4.  Figure 845 
was based on one generated using the residue-based diagram editor RbDe (55).   846 
 847 
Figure 3.  Binding of exendin 9-39 and GLP-1 7-36 amide to the WT hGLP-1R.  Homologous and 848 
heterologous competition binding assays were carried out on membranes prepared from HEK-293 cells 849 
transiently transfected with the WT hGLP-1R using 125I-exendin 9-39.  A homologous binding curve was 850 
fitted to the exendin 9-39 data and a sigmoidal curve to the GLP-1 7-36 amide data.  Data show total 851 
binding and are expressed as mean±SEM, n=5.   852 
 853 
Figure 4.  Ligand binding and cAMP generation by mutated hGLP-1Rs.  a,b) Homologous and 854 
heterologous competition binding assays were carried out on membranes prepared from HEK-293 cells 855 
transiently transfected with the WT and mutated hGLP-1Rs using 125I-exendin 9-39.  Homologous 856 
binding curves were fitted to the exendin 9-39 data and a sigmoidal curve to the GLP-1 7-36 amide data.  857 
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Data are expressed as mean±SEM with n=5 for the WT receptor and n=3 for each of the mutated 858 
receptors.  c) Transiently transfected cells were stimulated, in the presence of 1mM IBMX, for 1h with 859 
varying concentrations of either GLP-1 7-37 or forskolin (FSK, 50μM) at 37°C.  The cAMP was 860 
extracted and measured and expressed as a proportion of the response to FSK.  Sigmoidal concentration-861 
response curves were fitted.  Curves represent the means of n=7 for the WT receptor and n=3 for the 862 
mutated receptors (error bars omitted for clarity).  In each of the panels, data from the WT hGLP-1R and 863 
the Y152A (TM1), D198A (TM2), W284A (EC2), R310A (TM5) and H363A (TM6) mutations have 864 
been shown to demonstrate the range of alterations observed.  The binding affinities for GLP-1 7-36 865 
amide and exendin 9-39 (KI and Kd values respectively) and receptor expression levels derived from 866 
experiments on all receptor constructs are given in Table 2.  Similarly, potency estimates and Emax values 867 
for cAMP generation derived from experiments on all receptor constructs are given in Table 3.  868 
 869 
Figure 5.  The 3D model of the GLP-1R and example close-up images to highlight specific structural 870 
features and interactions.  a) The 3D model showing the hGLP-1R with GLP-1 bound.  GLP-1 is shown 871 
as black spheres (backbone atoms only). In all images the transmembrane helices are rainbow coloured: 872 
TM1, red; TM2, orange; TM3, yellow; TM4 green; TM5, blue; TM6, indigo; TM7, violet.  The N-873 
terminal domain is grey-blue.  Intracellular and extracellular loops are grey and the ligand (GLP-1) is 874 
black.  Within those amino acid residues in which some structure is shown, the colours of the helices are 875 
used to indicate carbon atoms whilst nitrogen is blue, oxygen is red and sulphur is yellow.  Non-bonded 876 
interactions are shown as dotted orange lines.  b)  The region surrounding Y152 (TM1) showing that this 877 
residue exists in a hydrophobic pocket interacting with some aromatic residues, providing a structured 878 
region.  Mutation to alanine (Y152A) would be expected to allow conformational collapse, possibly 879 
affecting the surrounding structures including EC1.  c)  The region surrounding D198 (TM2) showing 880 
the interaction of this residue with H7 at the N-terminal of GLP-1 (L:H7).  G295 (TM3) is also predicted 881 
to interact with L:H7 and K202 is predicted to interact with L:E9.  d)  The region surrounding W284 882 
(EC2) is shown to illustrate its role as a space-filling residue displaying an aromatic stacking interaction 883 
with Y289 (EC2) and F230 (TM3) that provides conformational support, particularly to EC2.  e) The 884 
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region surrounding R310, (TM5) showing a strong salt bridge with E364 (TM6).  f)  The region 885 
surrounding H363 (TM6) showing its position in an aromatic pocket formed by F390 and F393.  886 
 887 
Figure 6.  Helical wheel model of the transmembrane domain of the hGLP-1R.  Only the upper-half 888 
of the transmembrane domain is shown with the helices labelled I-VII.  The N-terminus of GLP-1 is also 889 
shown inserted between the transmembrane domain.  The diagram represents the hydrophilic residues as 890 
circles, hydrophobic residues as diamonds, potentially negatively charged residues as triangles, and 891 
potentially positively charged residues as pentagons. Hydrophobicity is colour coded: the most 892 
hydrophobic residues are green with the intensity of the green decreasing in relation to the loss of 893 
hydrophobicity.  Zero hydrophobicity is coded as yellow. Hydrophilic residues are coded red with pure 894 
red being the most hydrophilic (uncharged) residue and the intensity of red decreasing through orange 895 
with loss of hydrophilicity.  Residues that are potentially charged are light purple.  The interaction of 896 
D198 (TM2) with residue H7 of GLP-1 (L:H7) and the interaction of K202 (TM2) with L:E9 are shown.  897 
Residues mutated in the current study are circled in red.   898 
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